

No. R. 1212

1 December 2006

MEDICINES AND RELATED SUBSTANCES ACT, 1965**REGULATIONS RELATING TO A TRANSPARENT PRICING SYSTEM FOR
MEDICINES AND SCHEDULED SUBSTANCES****INFORMATION TO BE PUBLISHED BY MANUFACTURERS AND IMPORTERS
OF MEDICINES AND SCHEDULED SUBSTANCES BEFORE TAKING AN
INCREASE IN THE SINGLE EXIT PRICE**

The Director-General of Health has determined in accordance with Regulation 21 of the Regulations Relating to A Transparent Pricing System for Medicines and Scheduled Substances published in Government Gazette Number 28214 of 11 November 2005 that the following information in both electronic and document form must be communicated to the Directorate: Pharmaceutical Economic Evaluation within the National Department of Health by a manufacturer or importer respect of the medicine or scheduled substance in respect of which it intends to take an increase:

1. NAPPI Code;
2. brand name;
3. active ingredients;
4. strength and dosage form;
5. pack size;
6. ex manufacturer price for 2004;
7. ex manufacturer price as at 01 October 2004;
- a.** new increased ex manufacturer price;
9. logistics fee for 2004;
10. logistics fee as at 01 October 2006-11-01;
11. new logistics fee;
12. Value Added Tax;
13. New single exit price after the increase.

T D MSELEKU**DIRECTOR-GENERAL: HEALTH**